Iscar for Supplemental Care in Stage IV Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Key facts

Study ID

NCT00079794

Run by

National Center for Complementary and Integrative Health (NCCIH)

People needed

36

Starts

2001-09-01

Expected to finish

2004-02-01

Last updated by the study team

2008-01-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage IV NSCLC patients who receive standard chemotherapy

You may not qualify if…

• Known allergy to Viscum Album L.
• Concomitant use of other mistletoe products
• Concomitant use of mushroom glucan and proteoglycan extracts
• Concomitant use of thymus extract products
• Inability to self-report quality of life utilizing assessment tools
• Ongoing steroid or ACTH therapy
• Co-morbid immunocompromised state
• Pregnancy
• Participation in other clinical trials

Where it is running

• Thomas Jefferson University — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.